Key View 

• Pfizer has sold its biosimilars development facility in China, halting its biosimilar programmes in the country. 
• China’s biosimilar market is experiencing rapid growth, and all approvals for biosimilars are currently held by domestic companies. 
• Some international pharmaceutical companies have entered into partnerships with China

Key View: We forecast real household spending in China to recover over 2021, growing by 10.2% y-o-y, after the Covid-19 pandemic led to an estimated contraction of -1.2% y-o-y in 2020. The Chinese government has been relatively successful at curtailing the spread of the virus, having now gradually lifted many of the related restrictions

Key View

• The bearish momentum in outbound Chinese M&A is set to be short-lived, owing to a combination of returning global economic growth, an easing in tensions between the US and China and the need for China's domestic tech majors to seek growth offshore.
• While looking to boost Chinese consumer’s domestic demand story, the state is

Key View

• Advanced technologies are increasingly being integrated into the Chinese health system.
• Johnson & Johnson will increasingly invest in internet-based health services in China.
• Early adoption of new technologies will be key in transforming the Chinese healthcare market and driving a more patient-centric healthcare system.

China

Key View

• Demand for alternative protein continues to gain traction in China, with the Covid-19 pandemic accelerating a number of key drivers that will lead towards further consumer adoption of plant-based meat over the coming years.
• These include health worries, ethical concerns and food security issues. China continues to be an attractive

The Latest: The Communist Party of China (CPC) issued a communique on October 29, following the conclusion of its fifth plenary session (plenum) of the 19th CPC Central Committee. Key topics of the communique included the 14th Five-Year Plan (2021-2025) for the National Economic and Social Development and its long-term objective of achieving

Key View

• We at Fitch Solutions expect China to remain sharply focused on achieving the Fourth Industrial Revolution (4IR) in order to unlock productivity gains and secure greater technological self-sufficiency in order to head off structural headwinds to long-term growth.
• While existing initiatives, such as Made In China 2025, have yielded